- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06875102
Fatiga en el síndrome de Sjögren: 3 estrategias terapéuticas (FESSONA)
Fatiga en el síndrome de Sjögren: un ensayo controlado aleatorio de estrategias terapéuticas no farmacológicas combinadas
Unexplained fatigue is a frequent (60-70%) chronic complaint in Sjögren's syndrome (SjS) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (APA) programs, which are effective and feasible, but only to some extent. Hence, other therapeutic approaches, such as Acupuncture (ACU) or transcutaneous vagal nerve stimulation (tVNS), have been evaluated during the past years, with varying degrees of success in alleviating fatigue.
FESSONA has been designed as a randomized controlled monocentric trial, aiming at comparing the effects of 3 different programs on fatigue in SjS: APA alone, APA+ACU and APA+tVNS. Relevant controls will be included as well (sham ACU and simulated tVNS).
Multiple fatigue and SjS-related features will be measured before (at inclusion) and after (week 12) the intervention, as well as at week 24 and 48, to evaluate the short- and long-term impact of each program. Tolerance and feasibility will also be evaluated.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Martin KILLIAN, MD
- Número de teléfono: +33 (33)477 82 91 79
- Correo electrónico: martin.killian@chu-st-etienne.fr
Copia de seguridad de contactos de estudio
- Nombre: Florence RANCON, Chef de projet
- Número de teléfono: +33 (33)477829458
- Correo electrónico: florence.rancon@chu-st-etienne.fr
Ubicaciones de estudio
-
-
-
Saint-Etienne, Francia, 42055
- Reclutamiento
- Chu de Saint-Etienne
-
Sub-Investigador:
- David HUPIN, MD
-
Sub-Investigador:
- Hubert MAROTTE, MD PhD
-
Sub-Investigador:
- Baptiste GRAMONT, MD
-
Contacto:
- Martin KILLIAN, MD
- Número de teléfono: +33 (33) 4 77 82 91 79
- Correo electrónico: martin.killian@chu-st-etienne.fr
-
Contacto:
- Florence RANCON, Chef de projet
- Número de teléfono: +33 (33) 4 77 82 94 58
- Correo electrónico: florence.rancon@chu-st-etienne.fr
-
Sub-Investigador:
- Lucile GRANGE, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient affiliated or entitled to a social security scheme.
- Age > 18 years.
- Patient informed and having signed the information form and consent to participate in the study.
- Patient with Sjögren's syndrome according to ACR/EULAR 2016 or AECG 2002 criteria, usually followed up every year or more frequently
- Fatigue present for ≥ 6 months, without obvious explanation and/or specific treatment to conduct (e.g., disease's flare, chronic infection), with a current FACIT-F score < 34
Exclusion Criteria:
- Pre-existing atrial fibrillation or severe cardiac conduction disorders,
- Recent stroke or myocardial infarction (<6 months),
- Left ventricular ejection fraction <40% or severe heart failure (New York Heart Association functional class III or IV)
- Recurrent episodes of vasovagal syncope, or history of vagotomy
- People with dermatological problems in the area where the stimulation electrodes are to be placed
- Current episode of venous or arterial thrombosis
- Pregnancy or breastfeeding
- Patient under protective measures (legal protection, curatorship, guardianship)
- Inability or refusal to understand and/or sign informed consent to participate in the study, or to perform follow-up examinations required under the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: APA + Sham ACU + TVNS
|
Transcutaneous Vagus Nerve Stimulation (tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. In the groups receiving simulated tVNS, stimulation will be delivered to the ear lobe, which is devoid of vagal innervation. Stimulation will be delivered at a frequency of 20 Hz and a pulse width of 200 ms, while the stimulation amplitude will be individually titrated to 1 mA below the level that will lead to a mild unpleasant feeling, according to the parameters defined by Stavrakis et al (2017, 2020). The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention. |
|
Experimental: APA + ACU + TVN simulados
|
The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks acupoints will be Baihui (GV20); Zhongwan (CV12), Guanyuan (CV4), bilateral Zusanli (ST36) bilateral Taichong (LV3). The needles will remain for 30 min. Subjects will receive acupuncture twice a week during the 12-week intervention. Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in "simulated" mode. |
|
Comparador falso: APA + TVNS simulados + Acu Sham
|
The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention. Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in "simulated" mode. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in fatigue score assessed
Periodo de tiempo: Between inclusion (week 0) and visit V1 at 12 weeks (± 1 week from the end of the 12-week program)
|
Change in fatigue score assessed using the FACIT-F questionnaire (Functional Assessment of Chronic Illness Therapy - Fatigue; ranging from 0 to 52, 0 meaning extreme fatigue and 52 the total absence of fatigue) |
Between inclusion (week 0) and visit V1 at 12 weeks (± 1 week from the end of the 12-week program)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proporción (en %) de las 24 sesiones APA realizadas (al menos el 80 % de los ejercicios propuestos) en los diferentes grupos
Periodo de tiempo: Semana 48
|
Semana 48
|
|
|
FACIT-F score in the different groups
Periodo de tiempo: between inclusion (Week 0) and week 48
|
FACIT-F score at 48 weeks, in the different groups |
between inclusion (Week 0) and week 48
|
|
Root Mean Square of the Successive Differences in heart rate or RMSSD (in milliseconds)
Periodo de tiempo: at 12, 24 and 48 weeks,
|
Root Mean Square of the Successive Differences in heart rate or RMSSD (in milliseconds), measured from a nocturnal ECG recording by Holter ECG, in the different groups |
at 12, 24 and 48 weeks,
|
|
ClinESSDAI score
Periodo de tiempo: at 12, 24 and 48 weeks,
|
ClinESSDAI score (clinical part of the EULAR Sjögren's Syndrome Disease Activity Index; assessed on 11 "domains" corresponding to the main clinical manifestations of the disease; ranging from 0 to 135, a score of 0 meaning the existence of a disease and a score of 135 a disease whose activity would be maximal) in the different groups |
at 12, 24 and 48 weeks,
|
|
ESSPRI questionnaire (EULAR Sjögren's Syndrome Patient Reported Index)
Periodo de tiempo: at 12, 24 and 48 weeks
|
ESSPRI questionnaire (EULAR Sjögren's Syndrome Patient Reported Index); calculated as the mean of 3 self-measurement scales assessing fatigue, dryness and pain, each ranging from 0 to 10; 0 meaning the total absence of the symptom considered and 10 a symptom whose intensity would be at the maximum imaginable) in the different groups |
at 12, 24 and 48 weeks
|
|
HADS questionnaire (Hospital Anxiety and Depression Scale)
Periodo de tiempo: at 12, 24 and 48 weeks
|
HADS questionnaire (Hospital Anxiety and Depression Scale) composed of an anxiety score and a depression score both ranging from 0 to 21, 0 meaning the absence of symptoms of this type, and 21 the presence of an anxiety and/or major depressive state) in the different groups |
at 12, 24 and 48 weeks
|
|
Self-measurement questionnaire SF-36 (Short Form Health Survey 36)
Periodo de tiempo: between inclusion (Week 0) and week 48
|
Self-measurement questionnaire SF-36 (Short Form Health Survey 36); comprising 36 questions assessing 8 dimensions, namely physical functioning, role limitation due to physical problems, role limitation resulting from emotional problems, vitality (energy/fatigue), emotional well-being, social functioning, bodily pain, and perception of general and mental health; each dimension is represented by a score ranging from 0 to 100, with a low score signifying poor health perception in the dimension considered, and a high score signifying the opposite) |
between inclusion (Week 0) and week 48
|
|
EQ-5D-5L self-measurement questionnaire assessing 5 dimensions of health
Periodo de tiempo: at 12, 24, and 48 weeks,
|
EQ-5D-5L self-measurement questionnaire assessing 5 dimensions of health (mobility, autonomy, daily activities, pain/discomfort and anxiety/depression) with 1 question per domain, with the possibility of choosing 5 degrees of severity each time (1 corresponding to no difficulty for the domain and 5 corresponding to the maximum degree of difficulty in the domain), the total of the 5 notes of the 5 domains giving a score ranging from 5 to 25, and this questionnaire is associated with a visual analogue scale (VAS) allowing the patient to rate his state of health of the day from 0 (the worst state of health imaginable) to 100 (the best state of health imaginable), in the different groups |
at 12, 24, and 48 weeks,
|
|
Schirmer test
Periodo de tiempo: at 12, 24 and 48 weeks
|
the area of the graduated blotter that became wet after 5 min of placement on the lower eyelid of each eye, expressed in millimeters and as the average of the two eyes) at 12, 24 and 48 weeks, in the different groups |
at 12, 24 and 48 weeks
|
|
VO2max
Periodo de tiempo: at 12, 24 and 48 weeks
|
VO2max (in ml/min/kg; after metabolic test) in the different groups |
at 12, 24 and 48 weeks
|
|
Handgrip test
Periodo de tiempo: at 12, 24 and 48 weeks
|
Handgrip test (in kg; via a grip test on the dominant upper limb) in the different groups |
at 12, 24 and 48 weeks
|
|
Number of daily steps
Periodo de tiempo: at 12, 24 and 48 weeks
|
Number of daily steps measured via a connected watch on average over the week preceding the assessments at 12, 24 and 48 weeks, in the different groups |
at 12, 24 and 48 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Martin KILLIAN, MD
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades de la Boca
- Enfermedades Estomatognáticas
- Artritis
- Enfermedades Articulares
- Enfermedades reumáticas
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades de los ojos
- Artritis Reumatoide
- Xerostomía
- Enfermedades de las glándulas salivales
- Síndromes del ojo seco
- Enfermedades del aparato lagrimal
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades de la piel y del tejido conectivo
- Signos y síntomas
- Fatiga
- Síndrome de Sjogren
- Terapéutica
- Terapias complementarias
- Hidrolasas
- Enzimas
- Enzimas y coenzimas
- Hidrolasas peptídicas
- Metaloproteasas
- Exopeptidasas
- Metaloexopeptidasas
- Aminopeptidasas
- Terapia de acupuntura
- Glutamil aminopeptidasa
Otros números de identificación del estudio
- 24CH125
- ANSM (Otro identificador: 2024-A02116-41)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .